ERBB2 and breast carcinoma: Moreover, the ATEMPT trial demonstrated comparable safety profiles of adjuvant T‐DM1 to paclitaxel and trastuzamab within stage I HER2+ breast cancers; however, results from this phase II study found that women receiving T‐DM1 had a three‐fold greater risk of early discontinuation of therapy.25